Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
Ernexa Therapeutics released a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner discussing the significant unmet needs in ovarian cancer treatment and the potential of the company's lead product candidate, ERNA-101. Preclinical data show complete tumor elimination and 100% long-term survival in ovarian cancer models when ERNA-101 is …